Physician profile
Destin Black
NPI 1306062625
$60,887.50
in general payments reported to CMS, 2019-2025
22 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,178 · 2020: $13.59 · 2021: $6,409 · 2022: $20K · 2023: $20K · 2024: $12K · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Consulting Fee: $11K · Travel and Lodging: $6,725 · Food and Beverage: $2,787 · Gift: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,000.00 |
| Consulting Fee | $11,005.00 |
| Travel and Lodging | $6,724.53 |
| Food and Beverage | $2,787.44 |
| Gift | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $43,000.64 | 2019-2024 | Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $11,084.07 | 2022-2025 | Keytruda |
| Momentis Surgical INC. | $2,928.00 | 2023 | Anovo Surgical System |
| Pfizer INC. | $2,160.00 | 2024 | |
| Myriad Genetic Laboratories, INC. | $644.92 | 2022-2025 | Mychoice Cdx, Myrisk, Precisetumor |
| Glaxosmithkline, LLC. | $292.47 | 2019-2025 | Jemperli |
| Astrazeneca Pharmaceuticals LP | $167.34 | 2021-2024 | Tagrisso |
| Biom'Up Sa | $149.82 | 2019 | |
| Caris Mpi, INC. | $125.33 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $125.00 | 2023 | Tivdak |
| Conmed Corporation | $98.92 | 2022-2023 | Airseal |
| Karl Storz Endoscopy-America | $46.01 | 2019-2021 | |
| Solventum Corporation | $21.28 | 2025 | Prevena, V.A.C.Ulta |
| Tempus Ai, INC | $17.95 | 2025 | Xt Cdx |
| Therapeuticsmd, INC. | $14.78 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $10.97 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destin Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.